Individual differences |
Methods | Statistics | Clinical | Educational | Industrial | Professional items | World psychology |
Biological: Behavioural genetics · Evolutionary psychology · Neuroanatomy · Neurochemistry · Neuroendocrinology · Neuroscience · Psychoneuroimmunology · Physiological Psychology · Psychopharmacology (Index, Outline)
The follicle stimulating hormone receptor or FSH-receptor (FSHR) is a transmembrane receptor that interacts with the follicle stimulating hormone (FSH) and represents a G protein-coupled receptor (GPCR). Its activation is necessary for the hormonal functioning of FSH. FSHRs are found in the ovary, testis, and uterus.
- 1 FSHR gene
- 2 Receptor structure
- 3 Ligand binding and signal transduction
- 4 Action
- 5 Receptor regulation
- 6 FSHR abnormalities
- 7 History
- 8 See also
- 9 References
- 10 Further reading
- 11 External links
The FSHR consists of 695 amino acids and has a molecular mass of about 76 kDa. Like other GPCRs, the FSH-receptor possess seven membrane-spanning domains or transmembrane helices.
- The extracellular domain of the receptor is glycosylated.
- The transmembrane domain contains two highly conserved cysteine residues which build disulfide bonds to stabilize the receptor structure. A highly conserved Asp-Arg-Tyr triplet motif is present and may be of importance to transmit the signal.
- The C-terminal domain is intracellular and brief, rich in serine and threonine residues for possible phosphorylation.
Ligand binding and signal transduction
Upon binding FSH externally to the membrane, a transduction of the signal takes place that activates the G protein that is bound to the receptor internally. With FSH attached, the receptor shifts conformation and thus mechanically activates the G protein, which detaches from the receptor and activates the cAMP system.
It is believed that a receptor molecule exists in a conformational equilibrium between active and inactive states. The binding of FSH to the receptor shifts the equilibrium between active and inactive receptors. FSH and FSH-agonists shift the equilibrium in favor of active states; FSH antagonists shift the equilibrium in favor of inactive states. For a cell to respond to FSH only a small percentage (~1%) of receptor sites need to be activated.
Phosphorylation by cAMP-dependent protein kinases
Cyclic AMP-dependent protein kinases (protein kinase A) are activated by the signal chain coming from the G protein (that was activated by the FSH-receptor) via adenylate cyclase and cyclic AMP (cAMP). These protein kinases are present as tetramer with two regulatory units and two catalytic units. Upon binding of cAMP to the regulatory units, the catalytic units are released and initiate the phosphorylation of proteins leading to the physiologic action. The cyclic AMP-regulatory dimers are degraded by phosphodiesterase and release 5’AMP. DNA in the cell nucleus binds to phosphorylated proteins through the cyclic AMP response element (CRE) which results in the activation of genes.
The signal is amplified by the involvement of cAMP and the resulting phosphorylation. The process is modified by prostaglandins. Other cellular regulators are participate are the intracellular calcium concentration modified by phospholipase, nitric acid, and other growth factors.
The FSH receptor can also activate the extracellular signal-regulated kinases (ERK). 
In a feedback mechanism, these activated kinases phosphorylate the receptor. The longer the receptor remains active, the more kinases are activated, the more receptors are phosphorylated.
Upregulation refers to the increase in the number of receptor site on the membrane. Estrogen upregulates FSH receptor sites. In turn, FSH stimulates granulosa cells to produce estrogens. This synergistic activity of estrogen and FSH allows for follicle growth and development in the ovary.
The FSHR become desensitized when exposed to FSH for some time. A key reaction of this downregulation is the phosphorylation of the intracellular (or cytoplasmic) receptor domain by protein kinases. This process uncouples Gs protein from the FSHR. Another way to desensitize is to uncouple the regulatory and catalytic units of the cAMP system.
Downregulation refers to the decrease in the number of receptor sites. This can be accomplished by metabolizing bound FSHR sites. The bound FSH-receptor complex is brought by lateral migration to a "coated pit" where such units are concentrated and then stabilized by a framework of clathrins. A pinched-off coated pit is internalized and degraded by lysosomes. Proteins may be metabolized or the receptor can be recycled. Use of long-acting agonists will downregulate the receptor population.
Antibodies to FSHR can interfere with FSHR activity.
Women with 46 XX gonadal dysgenesis experience primary amenorrhea with hypergonadotropic hypogonadism. There are forms of 46 xx gonadal dysgenesis where abnormalities in the FSH-receptor have been reported and are thought to be the cause of the hypogonadism.
Alfred G. Gilman and Martin Rodbell received the 1994 Nobel Prize in Medicine and Physiology for the discovery of the G Protein System.
- Luteinizing hormone/choriogonadotropin receptor
- Simoni, Manuela, Jörg Gromoll & Eberhard Nieschlag (December 1997). The follicle-stimulating hormone receptor: biochemistry, molecular biology, physiology, and pathophysiology. Endocrine Reviews 18 (6): 739–773.
- Piketty, Vincent, Elodie Kara, Florian Guillou, Eric Reiter & Pascale Crepieux (June 2006). Follicle-stimulating hormone (FSH) activates extracellular signal-regulated kinase phosphorylation independently of beta-arrestin- and dynamin-mediated FSH receptor internalization. Reproductive Biology and Endocrinology 4 (33).
- Asatiani, K., Gromoll J., Eckardstein S.V., Zitzmann M., Nieschlag E., Simoni M. (June 2002). Distribution and function of FSH receptor genetic variants in normal men. Andrologia 34 (3): 172–176.
- La Marca, Antonio, Alfredo Carducci Artenisio, Gaspare Stabile, Francesco Rivasi & Annibale Volpe (December 2005). Evidence for cycle-dependent expression of follicle-stimulating hormone receptor in human endometrium. Gynecological Endocrinology 21 (6): 303–306.
- Delbaere, Anne, Guillaume Smits, Anne De Leener, Sabine Costagliola & Gilbert Vassart (April 2005). Understanding Ovarian Hyperstimulation Syndrome. Endocrine 26 (3): 285–290.
- Aittomäki, K., J.L.D. Lucena, P. Pakarinen, P. Sistonen, J. Tapanainen, J. Gromoll, R. Kaskikari, E.-M. Sankila, H. Lehvaslaiho, A.R. Engel, E. Nieschlag, I. Huhtaniemi & A. de la Chapelle (September 1995). Mutation in the follicle-stimulating hormone receptor gene causes hereditary hypergonadotropic ovarian failure. Cell 22 (82): 959–68.
- Loutradis, Dimitris, Eleni Patsoula, Vassilis Minas, Giorgos A. Koussidis, Aristeidis Antsaklis, Stylianos Michalas & Antonis Makrigiannakis (April 2006). FSH receptor gene polymorphisms have a role for different ovarian response to stimulation in patients entering IVF/ICSI-ET programs. Journal of Assisted Reproduction and Genetics 23 (4): 177–184.
- de la Chapelle A (1993). Disease gene mapping in isolated human populations: the example of Finland.. J. Med. Genet. 30 (10): 857–65.
- Amsterdam A, Hanoch T, Dantes A, et al. (2003). Mechanisms of gonadotropin desensitization.. Mol. Cell. Endocrinol. 187 (1-2): 69–74.
- Simoni M, Nieschlag E, Gromoll J (2003). Isoforms and single nucleotide polymorphisms of the FSH receptor gene: implications for human reproduction.. Hum. Reprod. Update 8 (5): 413–21.
- Delbaere A, Smits G, Olatunbosun O, et al. (2004). New insights into the pathophysiology of ovarian hyperstimulation syndrome. What makes the difference between spontaneous and iatrogenic syndrome?. Hum. Reprod. 19 (3): 486–9.
- Bose CK (2005). Role of nerve growth factor and FSH receptor in epithelial ovarian cancer.. Reprod. Biomed. Online 11 (2): 194–7.
- Wunsch A, Sonntag B, Simoni M (2007). Polymorphism of the FSH receptor and ovarian response to FSH.. Ann. Endocrinol. (Paris) 68 (2-3): 160–6.
- Kelton CA, Cheng SV, Nugent NP, et al. (1993). The cloning of the human follicle stimulating hormone receptor and its expression in COS-7, CHO, and Y-1 cells.. Mol. Cell. Endocrinol. 89 (1-2): 141–51.
- Tilly JL, Aihara T, Nishimori K, et al. (1992). Expression of recombinant human follicle-stimulating hormone receptor: species-specific ligand binding, signal transduction, and identification of multiple ovarian messenger ribonucleic acid transcripts.. Endocrinology 131 (2): 799–806.
- Gromoll J, Gudermann T, Nieschlag E (1992). Molecular cloning of a truncated isoform of the human follicle stimulating hormone receptor.. Biochem. Biophys. Res. Commun. 188 (3): 1077–83.
- Minegishi T, Nakamura K, Takakura Y, et al. (1991). Cloning and sequencing of human FSH receptor cDNA.. Biochem. Biophys. Res. Commun. 175 (3): 1125–30.
- Gromoll J, Ried T, Holtgreve-Grez H, et al. (1994). Localization of the human FSH receptor to chromosome 2 p21 using a genomic probe comprising exon 10.. J. Mol. Endocrinol. 12 (3): 265–71.
- Gromoll J, Dankbar B, Gudermann T (1994). Characterization of the 5' flanking region of the human follicle-stimulating hormone receptor gene.. Mol. Cell. Endocrinol. 102 (1-2): 93–102.
- Rousseau-Merck MF, Atger M, Loosfelt H, et al. (1993). The chromosomal localization of the human follicle-stimulating hormone receptor gene (FSHR) on 2p21-p16 is similar to that of the luteinizing hormone receptor gene.. Genomics 15 (1): 222–4.
- Jiang X, Dreano M, Buckler DR, et al. (1996). Structural predictions for the ligand-binding region of glycoprotein hormone receptors and the nature of hormone-receptor interactions.. Structure 3 (12): 1341–53.
- Aittomäki K, Herva R, Stenman UH, et al. (1996). Clinical features of primary ovarian failure caused by a point mutation in the follicle-stimulating hormone receptor gene.. J. Clin. Endocrinol. Metab. 81 (10): 3722–6.
- Tapanainen JS, Aittomäki K, Min J, et al. (1997). Men homozygous for an inactivating mutation of the follicle-stimulating hormone (FSH) receptor gene present variable suppression of spermatogenesis and fertility.. Nat. Genet. 15 (2): 205–6.
- Kotlar TJ, Young RH, Albanese C, et al. (1997). A mutation in the follicle-stimulating hormone receptor occurs frequently in human ovarian sex cord tumors.. J. Clin. Endocrinol. Metab. 82 (4): 1020–6.
- Glycoprotein Hormone Receptors: FSH. IUPHAR Database of Receptors and Ion Channels. International Union of Basic and Clinical Pharmacology.
- GRIS: Glycoprotein-hormone Receptor Information System
|Hypothalamic hormone receptors|
|Pituitary hormone receptors|
|Other hormone receptors|
|Other neuropeptide receptors|
Sex hormones and related agents (primarily G03, also L02, H01C) - human endogenous in CAPS
|PROGESTERONE, Desogestrel, Drospirenone, Dydrogesterone, Ethisterone, Etonogestrel, Ethynodiol diacetate, Gestodene, Gestonorone, Levonorgestrel, Lynestrenol, Medroxyprogesterone, Megestrol, Norelgestromin,
Norethisterone, Norethynodrel, Norgestimate, Norgestrel, Norgestrienone, Tibolone
|TESTOSTERONE, Androstanolone, Fluoxymesterone, Mesterolone, Methyltestosterone, (see also anabolic steroids)|
Antiandrogens: Bicalutamide, Cyproterone, Flutamide, Nilutamide, Spironolactone
|ESTRADIOL, ESTRIOL, ESTRONE, Chlorotrianisene, Dienestrol, Diethylstilbestrol, Ethinylestradiol, Fosfestrol, Mestranol, Polyestradiol phosphate|
Selective estrogen receptor modulator: Bazedoxifene, Clomifene, Fulvestrant, Raloxifene, Tamoxifen, Toremifene
Aromatase inhibitor: Aminogluthetimide, Anastrozole, Exemestane, Formestane, Letrozole, Vorozole
|ovulation stim.: Clomifene, Urofollitropin|
|agonist: Buserelin, Goserelin, Histrelin, Leuprorelin, Nafarelin, Triptorelin|
Abarelix, Cetrorelix, Ganirelix
|This page uses Creative Commons Licensed content from Wikipedia (view authors).|